Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer
Author:
Affiliation:
1. Department of Pharmacy; Cleveland Clinic; Cleveland Ohio
2. Cancer Institute; Cleveland Clinic; Cleveland Ohio
3. Outcomes Research; Cleveland Clinic; Cleveland Ohio
Publisher
Wiley
Subject
Pharmacology (medical)
Reference42 articles.
1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015
2. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data;Wagner;J Clin Oncol,2006
3. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial;Ford;Lancet Oncol,2014
4. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO);Thuss-Patience;Eur J Cancer,2011
5. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone;Kang;J Clin Oncol,2012
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer;PharmacoEconomics;2024-07-26
2. Cost-effectiveness analysis of bevacizumab combined with lomustine in the treatment of progressive glioblastoma using a Markov model simulation analysis;Frontiers in Public Health;2024-05-30
3. Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China;Expert Review of Pharmacoeconomics & Outcomes Research;2024-04-11
4. A Cost-effectiveness analysis of Nivolumab plus chemotherapy for the first-line treatment of locally advanced or metastatic gastric/GEJ/oesophageal adenocarcinoma in the United States of America;2024-02-27
5. Gastric Cancer;Tata Memorial Centre Textbook of Oncology;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3